Capstone Investment Advisors
KLRS

Capstone Investment Advisors’s Kalaris Therapeutics KLRS Stock Holding History

Capstone Investment Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,185
Closed -$20.6K – 2547
2024
Q1 		$20.6K Buy
1,185
+98
+9% +$1.6K ﹤0.01% 2265
2023
Q4 		$17K Buy
+1,087
New +$42.9K ﹤0.01% 2050

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capstone Investment Advisors's KLRS Position: Q2 2024 in Review

Capstone Investment Advisors sold out of Kalaris Therapeutics (KLRS) in Q2 2024, closing a stake of 1,185 shares — an estimated $20.6K sold.

Capstone Investment Advisors first reported a position in KLRS in Q4 2023 and held it in 2 quarters. The position peaked at $20.6K in Q1 2024. 71 funds tracked by Wall St. Rank hold KLRS as of Q2 2024.

  • Capstone Investment Advisors reported no remaining Kalaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Capstone Investment Advisors sold 1,185 Kalaris Therapeutics shares in Q2 2024, an estimated $20.6K.
  • Capstone Investment Advisors first reported a position in Kalaris Therapeutics in Q4 2023 and held it in 2 quarters.
  • Capstone Investment Advisors's Kalaris Therapeutics position peaked at $20.6K in Q1 2024.
  • 71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2024.

Based on Capstone Investment Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.